Treatment of extensive warts with etretinate

a clinical trial in 20 children

C. Gelmetti, D. Cerri, A. A. Schiuma, S. Menni

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

To evaluate the clinical effectiveness of etretinate in the treatment of papilloma virus infections, 20 children with extensive warts were given this oral retinoid for a period not exceeding three months at a dosage of 1 mg per kg per day. Sixteen patients showed complete regression of the disease without relapse, while in 4, lesions recurred after partial regression had been obtained. A follow-up of two years confirmed these findings. The results of this preliminary study are encouraging. Additional study is needed to determine the ultimate usefulness of etretinate in the treatment of refractory warts.

Original languageEnglish
Pages (from-to)254-258
Number of pages5
JournalPediatric Dermatology
Volume4
Issue number3
Publication statusPublished - 1987

Fingerprint

Etretinate
Warts
Clinical Trials
Retinoids
Papilloma
Virus Diseases
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Dermatology
  • Pediatrics, Perinatology, and Child Health

Cite this

Treatment of extensive warts with etretinate : a clinical trial in 20 children. / Gelmetti, C.; Cerri, D.; Schiuma, A. A.; Menni, S.

In: Pediatric Dermatology, Vol. 4, No. 3, 1987, p. 254-258.

Research output: Contribution to journalArticle

Gelmetti, C, Cerri, D, Schiuma, AA & Menni, S 1987, 'Treatment of extensive warts with etretinate: a clinical trial in 20 children', Pediatric Dermatology, vol. 4, no. 3, pp. 254-258.
Gelmetti, C. ; Cerri, D. ; Schiuma, A. A. ; Menni, S. / Treatment of extensive warts with etretinate : a clinical trial in 20 children. In: Pediatric Dermatology. 1987 ; Vol. 4, No. 3. pp. 254-258.
@article{23ef9affdad54ef19729c0e6c5a4891c,
title = "Treatment of extensive warts with etretinate: a clinical trial in 20 children",
abstract = "To evaluate the clinical effectiveness of etretinate in the treatment of papilloma virus infections, 20 children with extensive warts were given this oral retinoid for a period not exceeding three months at a dosage of 1 mg per kg per day. Sixteen patients showed complete regression of the disease without relapse, while in 4, lesions recurred after partial regression had been obtained. A follow-up of two years confirmed these findings. The results of this preliminary study are encouraging. Additional study is needed to determine the ultimate usefulness of etretinate in the treatment of refractory warts.",
author = "C. Gelmetti and D. Cerri and Schiuma, {A. A.} and S. Menni",
year = "1987",
language = "English",
volume = "4",
pages = "254--258",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Treatment of extensive warts with etretinate

T2 - a clinical trial in 20 children

AU - Gelmetti, C.

AU - Cerri, D.

AU - Schiuma, A. A.

AU - Menni, S.

PY - 1987

Y1 - 1987

N2 - To evaluate the clinical effectiveness of etretinate in the treatment of papilloma virus infections, 20 children with extensive warts were given this oral retinoid for a period not exceeding three months at a dosage of 1 mg per kg per day. Sixteen patients showed complete regression of the disease without relapse, while in 4, lesions recurred after partial regression had been obtained. A follow-up of two years confirmed these findings. The results of this preliminary study are encouraging. Additional study is needed to determine the ultimate usefulness of etretinate in the treatment of refractory warts.

AB - To evaluate the clinical effectiveness of etretinate in the treatment of papilloma virus infections, 20 children with extensive warts were given this oral retinoid for a period not exceeding three months at a dosage of 1 mg per kg per day. Sixteen patients showed complete regression of the disease without relapse, while in 4, lesions recurred after partial regression had been obtained. A follow-up of two years confirmed these findings. The results of this preliminary study are encouraging. Additional study is needed to determine the ultimate usefulness of etretinate in the treatment of refractory warts.

UR - http://www.scopus.com/inward/record.url?scp=0023577630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023577630&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 254

EP - 258

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 3

ER -